1734 — Sinphar Pharmaceutical Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareAdventurousSmall CapNeutral

Annual income statement for Sinphar Pharmaceutical Co, fiscal year end - December 31st, TWD millions except per share, conversion factor applied.

	2019 December 31st	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	2,395	2,388	2,434	2,857	2,963
Cost of Revenue
Gross Profit	941	876	889	1,091	1,091
Selling / General / Administrative Expenses
Research And Development
Total Operating Expenses	2,542	2,511	2,616	2,659	2,677
Operating Profit	-147	-122	-183	197	286
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	-86.7	-118	-185	245	306
Provision for Income Taxes
Net Income After Taxes	-148	-173	-205	164	357
Minority Interest
Net Income Before Extraordinary Items
Net Income	14	-28.5	-38.1	225	375
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Dilution Adjustment
Diluted Net Income	14	-28.5	-38.1	225	375
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	0.079	-0.171	-0.222	1.34	2.2
Dividends per Share